Do analysts rate BFRI or ELOX?

Eloxx Pharmaceuticals has a consensus target price of $38.33, suggesting a potential upside of 178.99%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eloxx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media prefer BFRI or ELOX?

In the previous week, Biofrontera had 3 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 6 mentions for Biofrontera and 3 mentions for Eloxx Pharmaceuticals. Biofrontera's average media sentiment score of 0.55 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TLPH or BFRI?

Talphera presently has a consensus price target of $3.00, suggesting a potential upside of 177.78%. Given Talphera's stronger consensus rating and higher possible upside, research analysts clearly believe Talphera is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, TLPH or BFRI?

Biofrontera has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Talphera $30K 1,868.76 -$14.29M -$0.27 N/A Biofrontera $46.18M 0.31 -$10.54M -$0.45 N/A

Is TLPH or BFRI more profitable?

Talphera has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Talphera's return on equity of -87.28% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -87.28% -51.36% Biofrontera -13.78% -145.81% -31.30%

Do analysts rate ZYBT or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, ZYBT or BFRI?

Zhengye Biotechnology has higher earnings, but lower revenue than Biofrontera. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 4.93 -$9.98M N/A N/A Biofrontera $46.18M 0.31 -$10.54M -$0.45 N/A

Does the media prefer ZYBT or BFRI?

In the previous week, Zhengye Biotechnology and Zhengye Biotechnology both had 6 articles in the media. Zhengye Biotechnology's average media sentiment score of 0.67 beat Biofrontera's score of 0.55 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biofrontera 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BFRI or HRTX?

Heron Therapeutics has a consensus target price of $2.00, suggesting a potential upside of 392.49%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Heron Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer BFRI or HRTX?

In the previous week, Biofrontera had 4 more articles in the media than Heron Therapeutics. MarketBeat recorded 6 mentions for Biofrontera and 2 mentions for Heron Therapeutics. Biofrontera's average media sentiment score of 0.55 beat Heron Therapeutics' score of 0.24 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INCR or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, INCR or BFRI?

InterCure has higher revenue and earnings than Biofrontera. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InterCure $78.47M 0.69 -$10.37M N/A N/A Biofrontera $46.18M 0.31 -$10.54M -$0.45 N/A

Biofrontera (BFRI) Competitors

$0.97 +0.05 (+5.57%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.97 0.00 (-0.31%)

As of 10/9/2026 07:14 PM Eastern

Compare

BFRI vs. ELOX, TLPH, ZYBT, HRTX, and INCR

Should you buy Biofrontera stock or one of its competitors? Biofrontera's main competitors and comparable companies include Eloxx Pharmaceuticals (ELOX), Talphera (TLPH), Zhengye Biotechnology (ZYBT), Heron Therapeutics (HRTX), and InterCure (INCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Biofrontera compare to Eloxx Pharmaceuticals?

Biofrontera (NASDAQ:BFRI) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Eloxx Pharmaceuticals has a consensus target price of $38.33, suggesting a potential upside of 178.99%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Biofrontera had 3 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 6 mentions for Biofrontera and 3 mentions for Eloxx Pharmaceuticals. Biofrontera's average media sentiment score of 0.55 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eloxx Pharmaceuticals has lower revenue, but higher earnings than Biofrontera. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$46.18M	0.31	-$10.54M	-$0.45	N/A
Eloxx Pharmaceuticals	$6.36M	8.73	-$5.99M	-$1.54	N/A

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Eloxx Pharmaceuticals' return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Biofrontera has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its share price is 196,142% less volatile than the broader market.

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Eloxx Pharmaceuticals beats Biofrontera on 10 of the 17 factors compared between the two stocks.

How does Biofrontera compare to Talphera?

Talphera (NASDAQ:TLPH) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Talphera presently has a consensus price target of $3.00, suggesting a potential upside of 177.78%. Given Talphera's stronger consensus rating and higher possible upside, research analysts clearly believe Talphera is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Talphera has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Talphera's return on equity of -87.28% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Biofrontera	-13.78%	-145.81%	-31.30%

Biofrontera has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,868.76	-$14.29M	-$0.27	N/A
Biofrontera	$46.18M	0.31	-$10.54M	-$0.45	N/A

In the previous week, Biofrontera had 5 more articles in the media than Talphera. MarketBeat recorded 6 mentions for Biofrontera and 1 mentions for Talphera. Biofrontera's average media sentiment score of 0.55 beat Talphera's score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Overall Sentiment
Talphera	Neutral
Biofrontera	Positive

Talphera has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

37.7% of Talphera shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Talphera and Biofrontera tied by winning 8 of the 16 factors compared between the two stocks.

How does Biofrontera compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

10.1% of Biofrontera shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zhengye Biotechnology has higher earnings, but lower revenue than Biofrontera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	4.93	-$9.98M	N/A	N/A
Biofrontera	$46.18M	0.31	-$10.54M	-$0.45	N/A

Zhengye Biotechnology has a beta of -2.31, meaning that its share price is 331% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

In the previous week, Zhengye Biotechnology and Zhengye Biotechnology both had 6 articles in the media. Zhengye Biotechnology's average media sentiment score of 0.67 beat Biofrontera's score of 0.55 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biofrontera	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zhengye Biotechnology has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Zhengye Biotechnology's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Biofrontera	-13.78%	-145.81%	-31.30%

Summary

Zhengye Biotechnology and Biofrontera tied by winning 6 of the 12 factors compared between the two stocks.

How does Biofrontera compare to Heron Therapeutics?

Biofrontera (NASDAQ:BFRI) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Biofrontera has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Heron Therapeutics has a consensus target price of $2.00, suggesting a potential upside of 392.49%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has a net margin of -13.78% compared to Heron Therapeutics' net margin of -22.52%. Biofrontera's return on equity of -145.81% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

Biofrontera has higher earnings, but lower revenue than Heron Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$46.18M	0.31	-$10.54M	-$0.45	N/A
Heron Therapeutics	$151.18M	0.51	-$20.19M	-$0.19	N/A

In the previous week, Biofrontera had 4 more articles in the media than Heron Therapeutics. MarketBeat recorded 6 mentions for Biofrontera and 2 mentions for Heron Therapeutics. Biofrontera's average media sentiment score of 0.55 beat Heron Therapeutics' score of 0.24 indicating that Biofrontera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Heron Therapeutics beats Biofrontera on 8 of the 14 factors compared between the two stocks.

How does Biofrontera compare to InterCure?

InterCure (NASDAQ:INCR) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

InterCure has higher revenue and earnings than Biofrontera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.69	-$10.37M	N/A	N/A
Biofrontera	$46.18M	0.31	-$10.54M	-$0.45	N/A

8.3% of InterCure shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Biofrontera had 5 more articles in the media than InterCure. MarketBeat recorded 6 mentions for Biofrontera and 1 mentions for InterCure. Biofrontera's average media sentiment score of 0.55 beat InterCure's score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Biofrontera	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InterCure has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

InterCure has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. InterCure's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Biofrontera	-13.78%	-145.81%	-31.30%

Summary

InterCure beats Biofrontera on 7 of the 13 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BFRI vs. The Competition

Export

Metric	Biofrontera	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.65M	$12.32B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-2.16	797.58	274.15	26.16
Price / Sales	0.31	939.82	635.98	113.06
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	1.08	10.71	11.21	6.34
Net Income	-$10.54M	$2.84B	$3.50B	$381.90M
7 Day Performance	-4.43%	-0.93%	-0.90%	-1.41%
1 Month Performance	-33.56%	-4.91%	-4.44%	-3.48%
1 Year Performance	1.04%	-4.13%	6.96%	1.16%

Biofrontera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BFRI Biofrontera	1.688 of 5 stars	$0.97 +5.6%	N/A	-6.7%	$13.65M	$46.18M	N/A	94	News Coverage Short Interest Decrease
ELOX Eloxx Pharmaceuticals	2.37 of 5 stars	$15.31 -0.7%	$38.33 +150.4%	N/A	$62.24M	$6.36M	N/A	7	Gap Up
TLPH Talphera	1.5898 of 5 stars	$1.16 -0.9%	$3.00 +158.6%	-15.0%	$60.73M	$30K	N/A	12	Positive News
ZYBT Zhengye Biotechnology	0.8936 of 5 stars	$1.20 -3.2%	N/A	-36.4%	$58.77M	$116.36M	N/A	269	News Coverage Gap Up
HRTX Heron Therapeutics	1.9502 of 5 stars	$0.31 +2.5%	$2.00 +538.0%	-69.0%	$58.10M	$154.90M	N/A	128	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BFRI) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biofrontera (BFRI) Competitors

BFRI vs. ELOX, TLPH, ZYBT, HRTX, and INCR

How does Biofrontera compare to Eloxx Pharmaceuticals?

Summary

How does Biofrontera compare to Talphera?

Summary

How does Biofrontera compare to Zhengye Biotechnology?

Summary

How does Biofrontera compare to Heron Therapeutics?

Summary

How does Biofrontera compare to InterCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biofrontera (BFRI) Competitors

BFRI vs. ELOX, TLPH, ZYBT, HRTX, and INCR

How does Biofrontera compare to Eloxx Pharmaceuticals?

Do analysts rate BFRI or ELOX?

Does the media prefer BFRI or ELOX?

Which has stronger earnings & valuation, BFRI or ELOX?

Is BFRI or ELOX more profitable?

Which has more volatility and risk, BFRI or ELOX?

Do insiders & institutionals hold more shares of BFRI or ELOX?

Summary

How does Biofrontera compare to Talphera?

Do analysts rate TLPH or BFRI?

Is TLPH or BFRI more profitable?

Which has better valuation & earnings, TLPH or BFRI?

Does the media favor TLPH or BFRI?

Which has more volatility & risk, TLPH or BFRI?

Do insiders and institutionals have more ownership in TLPH or BFRI?

Summary

How does Biofrontera compare to Zhengye Biotechnology?

Do analysts rate ZYBT or BFRI?

Do insiders and institutionals have more ownership in ZYBT or BFRI?

Which has stronger earnings & valuation, ZYBT or BFRI?

Which has more risk and volatility, ZYBT or BFRI?

Does the media prefer ZYBT or BFRI?

Is ZYBT or BFRI more profitable?

Summary

How does Biofrontera compare to Heron Therapeutics?

Which has more risk & volatility, BFRI or HRTX?

Do insiders and institutionals have more ownership in BFRI or HRTX?

Do analysts prefer BFRI or HRTX?

Is BFRI or HRTX more profitable?

Which has preferable valuation & earnings, BFRI or HRTX?

Does the media prefer BFRI or HRTX?

Summary

How does Biofrontera compare to InterCure?

Which has preferable earnings and valuation, INCR or BFRI?

Do institutionals and insiders have more ownership in INCR or BFRI?

Does the media prefer INCR or BFRI?

Do analysts recommend INCR or BFRI?

Which has more volatility & risk, INCR or BFRI?

Is INCR or BFRI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools